These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 22270540)
1. Toward a therapeutic window for antiplatelet therapy in the elderly. Gurbel PA; Ohman EM; Jeong YH; Tantry US Eur Heart J; 2012 May; 33(10):1187-9. PubMed ID: 22270540 [No Abstract] [Full Text] [Related]
2. Prasugrel versus clopidogrel. Pasceri V; Patti G; Di Sciascio G N Engl J Med; 2008 Mar; 358(12):1298-9; author reply 1299-301. PubMed ID: 18357638 [No Abstract] [Full Text] [Related]
3. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Silvain J; Cayla G; Hulot JS; Finzi J; Kerneis M; O'Connor SA; Bellemain-Appaix A; Barthélémy O; Beygui F; Collet JP; Montalescot G Eur Heart J; 2012 May; 33(10):1241-9. PubMed ID: 22067090 [TBL] [Abstract][Full Text] [Related]
4. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter? Goto S; Tomiya A Thromb Haemost; 2013 Feb; 109(2):177-8. PubMed ID: 23306954 [No Abstract] [Full Text] [Related]
5. Switching from prasugrel to clopidogrel: navigating in unknown waters. Angiolillo DJ; Rollini F JACC Cardiovasc Interv; 2013 Feb; 6(2):166-8. PubMed ID: 23428008 [No Abstract] [Full Text] [Related]
6. Tailoring antiplatelet therapy--insanity or good sense? Laine M; Toesca R; Frere C; Paganelli F; Bonello L Circ J; 2013; 77(5):1150-1. PubMed ID: 23524446 [No Abstract] [Full Text] [Related]
7. Improving outcomes with bivalirudin in primary percutaneous coronary intervention. Stone GW Eur Heart J; 2014 Sep; 35(34):2269-72. PubMed ID: 24872459 [No Abstract] [Full Text] [Related]
8. The FDA prasugrel review: adjudication of myocardial infarction controversy. Serebruany VL Cardiology; 2009; 114(2):126-9. PubMed ID: 19506374 [No Abstract] [Full Text] [Related]
9. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395 [TBL] [Abstract][Full Text] [Related]
10. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678 [TBL] [Abstract][Full Text] [Related]
11. Response to antiplatelet treatment: from genes to outcome. Giusti B; Abbate R Lancet; 2010 Oct; 376(9749):1278-81. PubMed ID: 20801497 [No Abstract] [Full Text] [Related]
13. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM; Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975 [TBL] [Abstract][Full Text] [Related]
14. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB; Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867 [TBL] [Abstract][Full Text] [Related]
15. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936 [TBL] [Abstract][Full Text] [Related]
16. Dual antiplatelet therapy after drug-eluting stents--how long to treat? Colombo A; Chieffo A N Engl J Med; 2014 Dec; 371(23):2225-6. PubMed ID: 25399657 [No Abstract] [Full Text] [Related]
17. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI? Graber MA; Dachs R; Darby-Stewart A Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017 [No Abstract] [Full Text] [Related]
18. Prasugrel, clopidogrel, and combining Swedish apples with American oranges. Serebruany VL Eur Heart J; 2006 Aug; 27(15):1886-7; author reply 1887-8. PubMed ID: 16801327 [No Abstract] [Full Text] [Related]
19. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. Angiolillo DJ; Saucedo JF; Deraad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Effron MB; J Am Coll Cardiol; 2010 Sep; 56(13):1017-23. PubMed ID: 20846599 [TBL] [Abstract][Full Text] [Related]
20. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. Cornel JH; Ohman EM; Neely B; Clemmensen P; Sritara P; Zamoryakhin D; Armstrong PW; Prabhakaran D; White HD; Fox KA; Gurbel PA; Roe MT; Am Heart J; 2014 Jul; 168(1):76-87.e1. PubMed ID: 24952863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]